Ensysce Biosciences Q2 net loss $2.2M; cash $3.8M; IRB approves key PF614 study

Ensysce Biosciences, Inc.

2023-Q2 EPS reported -$2.66 revenue$1,280,107

Net loss for Q2 2023 was $2.2 million versus $7.9 million in Q2 2022; EPS ($0.98) vs ($56.49).
Cash and cash equivalents $3.8 million at June 30, 2023, up from $1.4 million at March 31; increase driven by May 2023 public offering with $7.0 million gross proceeds.
R&D expenses decreased to $1.6 million in Q2 2023 from $5.3 million in Q2 2022 due to timing of clinical studies.
IRB approval received for PF614-201 protocol, a key Phase 3 study; End of Phase 2 meeting with FDA anticipated later this year.
Positive results from oral abuse potential study (PF614-104) and overdose protection Phase 1 study (PF614-MPAR-101) completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ensysce Biosciences, Inc. reported the second quarter of 2023 results: net income Net loss attributable to common stockholders for the second quarter of 2023 was $2.2 million.

Period: the second quarter of 2023
Net income: Net loss attributable to common stockholders for the second quarter of 2023 was $2.2 million
Result: reported results

Exact text from the filing

On August 11, 2023, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.